Clinical Efficacy of Adjuvant Chemotherapy in Patients With Locally Advanced Cervical Cancer Who Did Not Meet the NCCN Guidelines for Adjuvant Treatment After NACT Combined With Surgery

Inclusion criteria

• Clinical stage IB3-IIB cervical cancer (FIGO, 2018 standard) with the tumor diameter > 4cm before treatment.
• Pathologically confirmed cervical cancer, including cervical squamous cell carcinoma, adenocarcinoma and adenosquamous carcinoma.
• Age：18-70 years old.
• ECOG status score ≤1;
• WBC≥3.5*10^9/L, NEU≥1.5*10^9/L, Platelet≥80×10^9 /L; AST and ALT ≤1.5 times normal upper limit; Total bilirubin ≤1.5 times the upper limit of normal value; serum creatinine and blood urea nitrogen ≤the upper limit of normal value.
• Well-compliance and willing to keep in touch.
• Able to sign informed consent, including complying with the requirements and restrictions listed in the Informed Consent (ICF) and this protocol.

Exclusion criteria

• After 2-3 cycles of neoadjuvant chemotherapy, patients do not undergo laparotomic or laparoscopic extensive hysterectomy + pelvic lymph node dissection with cervical cancer foci sealed before dissection of the vagina and without uterine manipulator.
• Neoadjuvant chemotherapy regimens are different from postoperative adjuvant therapy regimens.
• Postoperative high risk factors: ① lymph node metastasis, ② parauterine infiltration, ③ positive surgical margin.
• Postoperative risk factors meet the Sedlis standard of the NCCN guideline.
• Participate in other clinical trials.
• Severe diseases of other important systems and organs.
• Persons without disposing capacity.
• Drug and/or alcohol abuse.
• Unable or unwilling to sign informed consents.
• Not eligible for the study judged by researchers.